Microcapspeculators.com is an informational website that is highly interested in exploring development stage companies, enroute to finding companies with the best potential
HENDERSON NV / ACCESSWIRE / July 24, 2018 / BioRestorative Therapies, Inc. (BRTX) is a small stem cell company, that has came across our radar screen. Just a few years ago BRTX was trading as high as $10 plus per share, and a high of $3.75 this year alone. Over the last few weeks interest in BRTX has been climbing, and the company has done higher volume days recently than ever before in BRTX trading history. We are putting this company on full breakout alert, and think everyone should immediately start researching the company.
BioRestorative Therapies, Inc. (BRTX)
Market cap: $11.3 million; current share price: $1.70
BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, recently reported the findings from Defined Health, which was engaged by the Company to conduct an independent review of BRTX-100, the Company's lead cell therapy candidate designed to treat chronic Lumbar Disc Disease (cLDD). Defined Health is a well-recognized business development and strategy consulting firm that has worked with many of the leading companies in the pharmaceutical, biotech and healthcare industries for over 25 years.
The Company plans to include the results of the review as it further refines its BRTX-100 program (that has been approved by the FDA to commence a Phase 2 clinical trial) by actively engaging in discussions with potential licensing partners, co-development and commercialization activities.
Since announcing this news, the Company has seen increased interest from investors this summer that could potentially lead to a major move in the near future.
Another oversold company in our opinion is AQXP.
Aquinox Pharmaceuticals Inc (NASDAQ: AQXP)
Market Cap: 72.88M, current share price: $3.10
Aquinox Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. Its lead product candidate is Rosiptor (Leadership 301), a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome.
Innovative biotech companies have always been saddled with the task of staying ahead of the curve when it comes to preparing for the future. Biotechnology is about improving human health and pursuing a passion for the greater good. Biotech companies are the futuristic spaceships most pharmaceutical companies don't even see flying above them. If big pharma doesn't prepare and embrace for the coming waves of change, it won't have an industry at all.
The last two years have marked massive changes in the biotech sector and how companies do business. These changes have motivated innovative biotech companies to take advantage of the opportunities that the current market offers. These same biotech companies will be the stepping stone to realizing the vision of a better, brighter future, and the industry as a whole is starting to catch up. There is no question that this tremendous swing in attitude towards innovative biotechnology will only benefit their technologies efficiency and effectiveness, increase investor funding and encourage future innovations.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and four thousand dollars total by Regal Consulting. LLC, for news commentary articles for BRTX. BRTX and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty eight hours after this article's distribution.
For Full Legal Disclaimer Click Here.
Contact Information:
Company Name: Microcap Speculators
Contact Person: Media Manager
Email: info@microcapspecualtors.com
Phone: 1-702-720-6310
Country: United States
Website: http://microcapspeculators.com/
SOURCE: ACR Communication, LLC
